450330.KQ
Hass
KOE · Healthcare · Medical - Specialties · KR
KRW 4,990.00
−0.10%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.1B | 16.6B | 16.2B | 16.0B | 14.9B |
| Cost of Revenue | 8.6B | 8.2B | 7.4B | 7.2B | 6.0B |
| Gross Profit | 7.4B | 8.4B | 8.7B | 8.8B | 8.9B |
| Operating Expenses | |||||
| R&D Expense | 2.5B | 3.4B | 1.3B | 933.6M | 1.0B |
| SG&A Expense | 3.9B | 2.8B | 2.6B | 3.0B | 2.1B |
| General & Admin Expense | 606.9M | 818.1M | 811.8M | 683.6M | 676.7M |
| Selling & Marketing Expense | 1.3B | 2.0B | 1.8B | 2.3B | 1.4B |
| Other Expenses | 5.0B | 3.4B | 3.6B | 3.3B | (4.3M) |
| Total Operating Expenses | 11.0B | 9.7B | 7.5B | 7.2B | 6.0B |
| Cost and Expenses | 19.7B | 17.9B | 14.9B | 14.4B | 12.0B |
| Operating Income (EBIT) | (3.6B) | (1.3B) | 1.2B | 1.6B | 2.9B |
| Non-Operating | |||||
| Interest Income | 540.1M | 627.9M | 423.1M | 32.2M | 44.3M |
| Interest Expense | 124.8M | 138.5M | 250.0M | 294.5M | 185.5M |
| Net Interest Income | 415.3M | 489.4M | 173.1M | (262.3M) | (141.2M) |
| Other Non-Op Income/Expense | 3.3B | 2.7B | 542.2M | (60.1M) | 119.8M |
| Non-Operating Income (excl Interest) | (318.6M) | — | (792.2M) | (234.3M) | (305.3M) |
| EBT (Pre-Tax Income) | (299.0M) | 1.4B | 1.8B | 1.6B | 3.0B |
| Income Tax Expense | (142.4M) | (103.7M) | (11.1M) | (242.1M) | 370.0M |
| Bottom Line | |||||
| Net Income | (156.6M) | 1.5B | 1.8B | 1.8B | 2.6B |
| Earnings from Cont. Ops | (156.6M) | 1.5B | 1.8B | 1.8B | 2.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (156.6M) | 1.5B | 1.8B | 1.8B | 2.6B |
| Per Share | |||||
| Basic EPS | (₩27) | ₩194 | ₩259 | ₩303 | ₩453 |
| Diluted EPS | (₩25) | ₩187 | ₩243 | ₩303 | ₩453 |
| Revenue Per Share | ₩2,074 | ₩2,026 | ₩2,337 | ₩2,706 | ₩2,555 |
| Shares | |||||
| Basic Shares Outstanding | 7.8M | 8.2M | 6.9M | 5.9M | 5.8M |
| Diluted Shares Outstanding | 7.8M | 8.2M | 7.4M | 5.9M | 5.8M |
| Profitability Metrics | |||||
| EBITDA | (471.9M) | 443.6M | 3.4B | 3.0B | 4.0B |
| D&A | 1.9B | 1.7B | 1.4B | 1.1B | 849.6M |
| EBIT | (2.3B) | (1.3B) | 2.0B | 1.8B | 3.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026